Skip to main content

Table 2 Clinical description and antibiotic therapy of B. pertussis positive and negative index cases

From: Hospital-based prospective study of pertussis in infants and close contacts in Tehran, Iran

  

N available

Total

B. pertussis cases

Negative cases

P valuea

N = 199

N = 40

N = 159

Cough duration at inclusion (days)

 

median (IQR)

199

8 (6-11)

10 (7.5-19.5)

8 (6-10)

0.004

 ≥ 14 days

n (%)

199

34 (17.1)

15 (37.5)

19 (12.0)

<0.001

Pertussis-like symptoms

 Nocturnal cough

n (%)

199

104 (52.3)

22 (55.0)

82 (51.6)

0.698

 Coughing spells

n (%)

199

163 (81.9)

34 (85.0)

129 (81.1)

0.570

 Apnea

n (%)

199

31 (15.6)

9 (22.5)

22 (13.8)

0.177

 Cyanosis

n (%)

199

130 (65.3)

31 (77.5)

99 (62.3)

0.070

 Inspiratory whoop

n (%)

199

32 (16.1)

9 (22.5)

23 (14.5)

0.216

 Difficult breathing in

n (%)

199

83 (41.7)

17 (42.5)

66 (41.5)

0.910

 Vomiting

n (%)

199

49 (24.6)

10 (25.0)

39 (24.5)

0.951

 Post tussif vomiting

n (%)

199

57 (28.6)

16 (40.0)

41 (25.8)

0.076

 Good conditions btw cough

n (%)

197

139 (70.6)

24 (60.0)

115 (73.3)

0.101

 Abnormal pulm auscultation

n (%)

193

26 (13.5)

8 (21.1)

18 (11.6)

0.127

>> sign of upper infection

n (%)

23

14 (60.9)

4 (50.0)

10 (66.7)

0.435

>> sign of lower infection

n (%)

9 (39.1)

4 (50.0)

5 (33.3)

Temperature

 ≤ 37.5

n (%)

199

190 (95.5)

38 (95.0)

152 (95.6)

0.871

 37.5-38.5

n (%)

9 (4.5)

2 (5.0)

7 (4.4)

Biological data

 Leukocytes (/mm3)

median (IQR)

191

10600 (8200-13200)

12900 (10100-17300)

9950 (7800-12400)

<0.001

 Lymphocytes (/mm3)

median (IQR)

179

6640 (5150-9265)

10080 (6020-14245)

6438 (5073-8421)

<0.001

 Hyperlymphocytosis (> 9000/μl)

n (%)

179

46 (25.7)

19 (54.3)

27 (18.8)

<0.001

 Neutrophiles (/mm3)

median (IQR)

179

2772 (1900-4350)

3290 (1800-4862)

2662 (1944-4047)

0.495

 Platelets (x103/mm3)

median (IQR)

193

407 (304-506)

474 (320-605)

392 (297-485)

0.040

 Hemoglobin (g/dl)

median (IQR)

195

10.5 (9.8-11.5)

11 (9.9-11.6)

10.5 (9.7-11.5)

0.415

 Mean corpuscular volume (MCV) (μ3)

median (IQR)

194

87 (82-93)

87 (81-93)

87 (82.5-93)

0.567

 SpO2

median (IQR)

196

95 (95-96)

95 (95-96)

95 (95-96)

0.856

Birth and weight

 Premature birth (< 37 weeks)

n (%)

197

22 (11.2)

2 (5.0)

20 (12.7)

0.165

 Low birth weight (< 2.5 kg)

n (%)

198

22 (11.1)

2 (5.0)

20 (12.7)

0.169

 Wasting

n (%)

188

54 (28.7)

13 (34.2)

41 (27.3)

0.403

 Stunting

n (%)

196

23 (11.7)

6 (15.0)

17 (10.9)

0.472

Antibiotic therapy before enrollment

 Yes

n (%)

188

120 (63.8)

24 (63.2)

96 (64.0)

0.923

 Macrolides

n (%)

 

82 (43.6)

16 (42.1)

66 (44.0)

0.833

 >> for > 48h before sampling

n (%)

82

37 (45.1)

10 (62.5)

27 (40.9)

0.119

Last clinical evaluation

 Time after inclusion (days)

median (IQR)

195

14 (13-14)

14 (13-14)

14 (13-14)

0.933

 Full recovery

n (%)

195

164 (84.1)

27 (67.5)

137 (88.4)

0.002

 Healing with persistent cough

n (%)

195

27 (13.9)

10 (25.0)

17 (11.0)

-

 No improvement

n (%)

195

2 (1.0)

2 (5.0)

0 (0-)

-

Death

n (%)

195

2 (1.0)

1 (2.5)

1 (0.7)

-

Hospitalization

 Yes

n (%)

199

192 (96.5)

39 (97.5)

153 (96.2)

0.696

  1. aP values in bold indicate p < 0.05